Zymeworks BC Inc (ZYME): Insights At A Glance

Zymeworks BC Inc (ZYME) concluded trading on Thursday at a closing price of $10.52, with 0.47 million shares of worth about $4.93 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 69.13% during that period and on March 28, 2024 the price saw a gain of about 2.14%. Currently the company’s common shares owned by public are about 70.12M shares, out of which, 65.91M shares are available for trading.

However, the stock later moved at a day high price of 10.57, or with a gain of 2.14%. Stock saw a price change of -1.22% in past 5 days and over the past one month there was a price change of -12.77%. Year-to-date (YTD), ZYME shares are showing a performance of 1.25% which increased to 30.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.01 but also hit the highest price of $13.14 during that period. The average intraday trading volume for Zymeworks BC Inc shares is 568.61K. The stock is currently trading -5.50% below its 20-day simple moving average (SMA20), while that difference is down -5.73% for SMA50 and it goes to 20.19% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Zymeworks BC Inc (NASDAQ: ZYME) currently have 70.12M outstanding shares and institutions hold larger chunk of about 92.57% of that.

The stock has a current market capitalization of $749.23M and its 3Y-monthly beta is at 1.13. It has posted earnings per share of -$1.74 in the same period. It has Quick Ratio of 7.41 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZYME, volatility over the week remained 2.27% while standing at 4.12% over the month.

Analysts are in expectations that Zymeworks BC Inc (ZYME) stock would likely to be making an EPS of -$0.29 in the current quarter, while forecast for next quarter EPS is -$0.08 and it is -$0.78 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.42 which is -$0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.36 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 43.22% while it is estimated to increase by 89.35% in next year. EPS is likely to grow at an annualized rate of 11.00% for next 5-years, compared to annual growth of -6.52% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on March 21, 2023 offering an Overweight rating for the stock and assigned a target price of $12 to it. Coverage by H.C. Wainwright stated Zymeworks BC Inc (ZYME) stock as a Neutral in their note to investors on January 04, 2023, suggesting a price target of $8 for the stock. On December 20, 2022, Jefferies Upgrade their recommendations, while on November 01, 2022, H.C. Wainwright Downgrade their ratings for the stock with a price target of $8. Stock get a Mkt perform rating from SVB Leerink on October 21, 2022.

Most Popular

Related Posts